跳至主要内容
临床试验/NCT00279227
NCT00279227Unknown不适用

Role of Epicardial Adipose Tissue in Coronary Artery Disease

Hamilton Health Sciences Corporation1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2006年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
50
试验地点
1

研究概览

简要总结

We sight to evaluate whether patients with coronary artery disease (CAD) have more epicardial fat than patients without CAD, which would suggest that epicardial fat may be more than an "innocent bystander" and be actively involved in the disease process. Its role as a modulator of vascular response and myocardial function could potentially lead to new areas of cardiac research. We also sight to evaluate whether epicardial fat from patients with CAD releases more adipokines than subcutaneous fat from these patients which could prompt studies into the differential regulation of adipokine secretion in this tissue. Thus for e.g., the use of thiazolidinediones (glitazones), statins, ARBs or other compounds that can specifically modulate adipokine secretion could be explored to determine their benefit in ameliorating the effects attributable to increased epicardial fat.

研究设计

研究类型
Observational
观察模型
Defined Population
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients elegible for elective cardiac surgery are elegible
  • Ability to provide written informed consent in accordance with GCP guidelines and local legislations.
  • > 18 years of age

排除标准

  • Control patients will not have clinical signs of CAD and will show normal coronary arteries on angiography.
  • Any medical, social or geographic condition, which, in the opinion of the investigator would not allow safe or reliable completion of the protocol.

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验